PubMed Health⌕ Search

Biomedical subjects

G Pagnini

Publications and source records attributed to G Pagnini.

At least 19 recordsLinked to original sources
PubMed1988

Regional distribution and species variation of prolactin binding sites in the brain.

The binding of 125I-labeled ovine prolactin (125I-oPRL) to membranes from different brain regions of pigeon, rabbit, rat, pig, calf, horse, and ewe was studied. The hypothalamus from rabbit, pig, horse, and pigeon showed a low but specific binding for 125I-oPRL clearly different from the other brain regions examined (cortex and cerebellum), whereas in the brain from rat, calf, and ewe the binding was very small and quite uniform in the various regions. Also the membranes from choroid plexus of rabbit, pig, calf, and horse showed an evident specific binding for prolactin. The binding of 125I-oPRL to hypothalamus and choroid plexus membranes from rabbit and horse was inhibited in a dose-dependent manner by unlabeled oPRL and hGH but not by many other polypeptide hormones. Scatchard analysis of the binding revealed the presence of binding sites with low capacity and high affinity for ovine ligand.

Animals↗
PubMed1978

[Neuropsychopharmacological effects of TCDD].

It has been found that TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin), in rats, endoperitoneally or orally administered at dose of 1-10 mcg/kg, provokes irritability, aggressivity and restlessness (increase of spontaneous crossings in the shuttle box). The TCDD does not modify the conditioned avoidance (C.A.) or the conflictual situation. In "vitro" the TCDD stimulates directly the striatal and hypothalamic adenylate cyclase of rat. The TCDD increases the stimulation produced by dopamine on striatal adenylate cyclase. Haloperidol (dopamine antagonist) inhibits the stimulation produced by TCDD. TCDD does not significantly modify the stimulation by hystamine on hypothalamic adenylate cyclase. Cimetidine (H2) antagonist) causes a remarkable increase of the TCDD stimulating effect.

Adenylyl Cyclases↗
PubMed1978

Effects of bromocriptine on adenylate cyclase and phosphodiesterase activities of rat striatum.

The activity of 2-bromo-alpha-ergokryptine (bromocriptine) (5 mg kg-1, i.p.) on adenylate cyclase and on phosphodiesterase (PDE-PDE II) of rat striatum, has been examined both in vitro and in vivo. In vitro and in vivo bromocriptine stimulated adenylate cyclase activity, but reduced the stimulating effect of dopamine on adenylate cyclase activity. Bromocriptine showed a dose-dependent biphasic action on phosphodiesterases in vitro while in vivo it stimulated them. The results obtained proved bromocriptine to have an agonist-antagonist action at striatal dopamine receptor level, with a relevant effect on the cAMP system.

Adenylyl Cyclases↗